MindMed (NASDAQ: MNMD) (NEO: MMED) (DE: MMQ), announced Thursday that it had obtained authorization from the local Swiss ethics committee to conduct the first clinical trial on mescaline.
The psychedelic medicine biotech company noted that the study will examine the effects of various “doses of mescaline and the role of the serotonin 5-HT2A receptor in mescaline-induced altered state of consciousness.”
Mescaline is a classic serotonergic hallucinogen similar to LSD psilocybin, famous for its long, non-regulated history of spiritual use.
The research is scheduled to begin in May at the University Hospital Basel Liechti Lab in Basel, Switzerland.
Why It Matters
MindMed said that the importance of this study lies in the fact that valid studies on the effects …